» Articles » PMID: 35611347

Delayed Tuberculosis Treatment and Cost of Care in a Low-Incidence Country

Overview
Date 2022 May 25
PMID 35611347
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tuberculosis (TB) elimination requires high-quality, timely care. In countries with a low incidence of TB, such as Ireland, delayed diagnosis is common. This evaluation aimed to determine the factors that predict patient-related and health care provider-related delays in TB management and to establish how TB care cost is affected by care delays.

Methods: Health care records of patients with signs and symptoms of TB evaluated by a tertiary service in Ireland between July 1, 2018, and December 31, 2019, were reviewed to measure and determine predictors of patient-related delays, health care provider-related delays, and the cost of TB care. Outcomes were compared against benchmarks derived from the literature.

Results: Thirty-seven patients were diagnosed with TB, and 51% (19/37) had pulmonary TB (PTB). The median patient-related delay was 60 days among those with PTB, greater than the benchmark derived from the literature (38 days). The median health care provider-related delay among patients with PTB was 16 days and, although similar to the benchmark (median, 22 days; minimum, 11 days; maximum, 36 days), could be improved. The health care provider-related delay among patients with EPTB was 66 days, greater than the benchmark (42 days). The cost of care was €8298 and, while similar to that reported in the literature (median, €9319; minimum, €6486; maximum, €14 750), could be improved. Patient-related delays among those with PTB predicted care costs.

Conclusions: Patient-related and health care provider-related delays in TB diagnosis in Ireland must be reduced. Initiatives to do so should be resourced.

Citing Articles

Diagnostic value of SAT-TB in smear-negative pulmonary tuberculosis: A diagnostic accuracy study.

Zhao X, Cui K, Bai L, Xu S, Liu W, Shang J Medicine (Baltimore). 2024; 103(50):e40907.

PMID: 39686443 PMC: 11651478. DOI: 10.1097/MD.0000000000040907.


Ending tuberculosis: the cost of missing the World Health Organization target in a low-incidence country.

OConnell J, McNally C, Stanistreet D, de Barra E, McConkey S Ir J Med Sci. 2022; 192(4):1547-1553.

PMID: 36121600 PMC: 9483873. DOI: 10.1007/s11845-022-03150-3.

References
1.
Connolly S, Wren M . Unmet healthcare needs in Ireland: Analysis using the EU-SILC survey. Health Policy. 2017; 121(4):434-441. DOI: 10.1016/j.healthpol.2017.02.009. View

2.
Mathiasen V, Andersen P, Johansen I, Lillebaek T, Wejse C . Clinical features of tuberculous lymphadenitis in a low-incidence country. Int J Infect Dis. 2020; 98:366-371. DOI: 10.1016/j.ijid.2020.07.011. View

3.
Asres A, Jerene D, Deressa W . Delays to treatment initiation is associated with tuberculosis treatment outcomes among patients on directly observed treatment short course in Southwest Ethiopia: a follow-up study. BMC Pulm Med. 2018; 18(1):64. PMC: 5930812. DOI: 10.1186/s12890-018-0628-2. View

4.
Sulis G, Agliati A, Pinsi G, Bozzola G, Foccoli P, Gulletta M . Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.02345-2017. View

5.
Gagliotti C, Resi D, Moro M . Delay in the treatment of pulmonary TB in a changing demographic scenario. Int J Tuberc Lung Dis. 2006; 10(3):305-9. View